- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: batoclimab.
Displaying page 1 of 1.
| EudraCT Number: 2022-002839-66 | Sponsor Protocol Number: IMVT-1401-3203 | Start Date*: 2023-09-07 | |||||||||||
| Sponsor Name:Immunovant Sciences, GmbH | |||||||||||||
| Full Title: An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED) | |||||||||||||
| Medical condition: Thyroid Eye Disease (TED) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Not Authorised) LV (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-002787-68 | Sponsor Protocol Number: IMVT-1401-3201 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Immunovant Sciences, GmbH | |||||||||||||
| Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) | |||||||||||||
| Medical condition: Thyroid Eye Disease (TED) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-002788-30 | Sponsor Protocol Number: IMVT-1401-3202 | Start Date*: 2023-07-13 | |||||||||||
| Sponsor Name:Immunovant Sciences, GmbH | |||||||||||||
| Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) | |||||||||||||
| Medical condition: Thyroid Eye Disease (TED) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) LV (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-002718-17 | Sponsor Protocol Number: IMVT-1401-2401 | Start Date*: 2023-06-19 | |||||||||||
| Sponsor Name:Immunovant Sciences, GmbH | |||||||||||||
| Full Title: A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | |||||||||||||
| Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-000249-42 | Sponsor Protocol Number: IMVT-1401-3101 | Start Date*: 2022-10-12 | |||||||||||
| Sponsor Name:Immunovant Sciences GmbH | |||||||||||||
| Full Title: A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Genera... | |||||||||||||
| Medical condition: Generalized Myasthenia Gravis (gMG) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-002894-27 | Sponsor Protocol Number: IMVT-1401-2501 | Start Date*: 2023-04-03 | |||||||||||
| Sponsor Name:Immunovant Sciences GmbH | |||||||||||||
| Full Title: A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants with Graves’ Disease (GD) | |||||||||||||
| Medical condition: Graves` disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-004676-35 | Sponsor Protocol Number: RVT-1401-2001 | Start Date*: 2019-10-23 | |||||||||||
| Sponsor Name:Immunovant Sciences GmbH | |||||||||||||
| Full Title: ASCEND GO2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients with Active, Moderate to Severe Graves’ Ophthalmopathy | |||||||||||||
| Medical condition: Graves´Ophthalmopathy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.